Recruiting
Phase 1
Phase 2

Tributyrin

Sponsor:

Prabesh Kanel

Code:

NCT07863180

Conditions

Parkinson Disease

Multiple System Atrophy

Progressive Supranuclear Palsy(PSP)

Eligibility Criteria

Sex: All

Age: 45+

Healthy Volunteers: Not accepted

Interventions

Tributyrin

Placebo

Study Details

Brief summary:

This research is studying a supplement called tributyrin in people with Progressive Supranuclear Palsy (PSP) to learn about its safety and tolerability as a potential treatment. The goal of this research study is to see if a similar supplementation regimen and virtual testing is feasible for people with PSP.

Conditions

Parkinson Disease

Multiple System Atrophy

Progressive Supranuclear Palsy(PSP)

Study ID

NCT07863180

Start date

Sep, 2026

Status verified date

Oct, 2026

Completion date

May, 2027

Anticipated

Primary completion date

May, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 45+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Male or Female, age 45 years and over.
  • Diagnosis of PSP-Richardson syndrome (RS) based on Movement Disorder Society (MDS) Criteria, including

1. Vertical supranuclear gaze palsy.
2. Repeated unprovoked falls OR tendency to fall on the pull test within 3 years.
  • Access to the internet and webcam for virtual visits.
  • Presence of a caregiver.

Exclusion Criteria:

  • Recent history of significant, uncontrolled GI disease such as Gastroesophageal reflux disease, colorectal cancer.
  • Significant metabolic or uncontrolled medical comorbidity.
  • Regular use of typical anti-cholinergic drugs.
  • Women of child-bearing potential, or who are pregnant and/or nursing.
  • Suicidal ideation, as indicated by a response of 2 or 3 on question 9 of the Beck Depression Inventory.
  • Any other condition or criterion that, in the opinion of the investigators, would preclude safe and meaningful participation in the study.

Study Design

Enrollment

15 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Tributyrin

Participants will take 500mg three times a day (TID) tributyrin supplement for 90 days +/- 7 days.

placebo comparator: Placebo

Participants will take 500mg placebo for 90 days +/- 7 days.

Interventions

Tributyrin

Post-biotic short chain fatty acid dietary supplement. Participants will take 500mg TID tributyrin supplement for 90 days +/- 7 days.

Placebo

Participants will take 500mg TID placebo for 90 days +/- 7 days.

Primary outcome measure

  • Tolerability of tributyrin [ Time Frame: Visit 7 (approximately day 90) ]
  • Safety of tributyrin [ Time Frame: Up to visit 7 (approximately day 90) ]

Central Contacts and Locations

Central contacts

Nathan Alexander

734-998-8422natealex@med.umich.edu

Robert Vangel, BSc

734-936-1168rvangel@med.umich.edu

Locations

Domino's Farms

Recruiting

Ann Arbor, Michigan, United States, 48105

Contacts

Nathan Alexander

734-998-8422natealex@med.umich.edu

Robert Vangel, BSc

734-936-1168rvangel@med.umich.edu

Principal Investigator:

Prabesh Kanel, PhD

More Information

Sponsor

Prabesh Kanel

Last update posted

Oct 7, 2026

Last verified

Oct, 2026

Keywords

  • short chain fatty acid
  • fecal microbiota transplantation
  • Butyric acid
  • Tributyrin

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-08. This information was provided to ClinicalTrials.gov by Prabesh Kanel on 2026-10-07. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.